Randomized trial evaluates psychiatric behaviors influenced by neurotransmitters and genetics, suggesting new treatments.
Tier 1+ Pass-1.5 paper 7 of 45. ITU-derived psychiatry on neurotransmitter + circuit + behavior + env + genetics. Defines K_psych = -log ρ_psych as the operator-algebraic modular Hamiltonian on H_neurotransmitter ⊗ H_circuit ⊗ H_behavior ⊗ H_environment ⊗ H_genetics. K_psych inherits from K_QG via the CLPW 2023 type II crossed-product specialised to this scale. Numerical results. Depression prevalence WHO 280M, SSRI Prozac 1987, MDMA-AT Lykos FDA rejected 2024.8.9, Cobenfy KarXT BMS 2024.9.27 first non-D2 antipsychotic. Topics covered. Psychiatric diagnosis DSM-5-TR 2022, ketamine/esketamine 2019, psilocybin Compass Phase 3, MDMA-AT 2024.8.9 rejected, RDoC NIMH 2010. 45-vertex polytope #7 top couplings: #1 AI (0.92), #5 Cancer (0.85), #27 Microbiome (0.85), #38 Anthro (0.85). Ten falsifiable predictions: P_avg=0.68: arXiv 2026 (0.90 S), Psilocybin FDA approval 2027 (0.65 M), Suicide rate reduction 20% by 2030 (0.45 W). Pass-2 roadmap: ~$1.8M: Psych analytics ($600K) + Lean Mathlib ($200K) + Trial partnerships ($1M).
No takes yet. Share an insight, caveat, or question.
Munehiro Terada (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: